Most linked-to pages
From Glioblastoma Treatments
Jump to navigationJump to search
Showing below up to 50 results in range #151 to #200.
- TMZ (2 links)
- Tamoxifen (2 links)
- Thalidomide (2 links)
- Thyroid Hormone T4 (Thyroxine) Suppression (2 links)
- Trial of three drugs plus temodar (2 links)
- Typically, tumors recur within 6 months of standard treatment. (2 links)
- Under investigation; early results promising, especially in combination therapies (2 links)
- Valproic acid (2 links)
- Variable across studies (2 links)
- Varies; can include fatigue, headache, localized reactions at infusion site (2 links)
- Varies; earlier phases showed median overall survival up to 38 months in phase I trial participants. (2 links)
- Wilms Tumor 1 (WT1) Peptide Vaccine (2 links)
- Wilms Tumor Peptide Vaccine (2 links)
- Category:Nutraceuticals (2 links)
- Category:Other Chemotherapy and Cancer Drugs (2 links)
- Property:Has Usefulness Explanation (2 links)
- 1 out of 16 patients was alive after one year. (2 links)
- 6 out of 14 patients were alive after one year (2 links)
- Not explicitly detailed in recent reviews (2 links)
- Recent meta-analyses suggest potential for improving cancer treatment outcomes (2 links)
- Median survival with standard treatment: 17.4 months (2 links)
- Not directly specified; improvements noted in selected patient analyses (2 links)
- Post-hoc analysis with at least six months of Valcyte use: median survival of 24 months, 4-year survival of 27% (2 links)
- Valganciclovir (Valcyte) (2 links)
- PSK (Polysaccharide Krestin) and other polysaccharides (2 links)
- Gamma-Linolenic Acid (GLA) (2 links)
- Perillyl Alcohol/Limonene (2 links)
- Early clinical evaluation in a small case series (2 links)
- Majority of newly diagnosed patients without disease progression for periods extending to 2-3 years, and in one case, 87 months (2 links)
- Not specified in the provided information (2 links)
- Varies; one GBM patient had a significant tumor shrinkage, others showed extended progression-free survival, including one patient surviving 87 months post-diagnosis (2 links)
- Fatigue, dizziness, nausea, mouth irritation (2 links)
- Phase 2 clinical trial in 2021 indicated for glioblastoma (2 links)
- Not applicable; research has not extensively measured progression-free survival in cancer patients (2 links)
- Preclinical studies and early clinical trials (2 links)
- Not specifically documented; focus on overall survival improvements (2 links)
- 23 months median survival, with 47% at 2 years (2 links)
- Hematological toxicity, nausea, and neurological effects (2 links)
- Not specified; primary focus has been on edema reduction and potentially improved quality of life (2 links)
- Not specified; studies have focused on steroid requirements and edema control (2 links)
- Chronotherapy with TMZ could significantly extend survival times, particularly for patients with MGMT methylated tumors. (2 links)
- Early clinical trials show promising results in improving overall survival and progression-free survival in various cancers, including potential benefits for GBM. Ongoing trials will provide more definitive data. (2 links)
- Hyperthermia has shown potential in enhancing the effectiveness of radiation and chemotherapy, improving overall survival and progression-free survival rates in glioblastoma patients. (2 links)
- Metronomic low-dose TMZ may offer a viable option for patients with recurrent GBM, providing a balance between efficacy and reduced toxicity compared to standard dosing. Further research is ongoing to confirm these benefits. (2 links)
- Shows a clinically meaningful extension of survival in both newly diagnosed and recurrent GBM patients. Offers fresh hope by potentially improving outcomes in a challenging treatment landscape. (2 links)
- Shows promise based on significant improvements in overall survival and disease-free survival in high-risk AML patients; ongoing research needed to fully establish efficacy in other cancers (2 links)
- The vaccine shows promise, especially in extending progression-free survival in newly diagnosed GBM. It offers a novel approach by leveraging the patient's immune system, potentially improving outcomes in a disease with few effective treatments. (2 links)
- This vaccine represents a promising strategy by targeting CMV antigens present in GBM cells, potentially extending survival significantly beyond standard treatments. Initial results suggest substantial benefits for certain patient groups. (2 links)
- Gamma Knife Radiosurgery (GKRS) for GBM (2 links)
- Median overall survival for GBM is typically 15-17 months from diagnosis, or 8 months from recurrence (2 links)
